**ASX ANNOUNCEMENT**

# Lumos Diagnostics Quarterly Activity Statement and Cash Flow Report

## Key Highlights from the Third Quarter of Financial Year 2025

- **Revenue of US$3.5 million for the quarter**, up 21% compared to the prior quarter (Q2 FY25).
- **Product revenue** was up 17% on Q2 and **Services revenue** was up 22% on Q2 FY25.
- **Total YTD revenue is US$9.8 million at quarter's end,** up 44% compared to the prior year.
- **Additional FebriDx® distribution partnership agreements completed** in the U.S. with MedPro Associates and the US Defense Logistics Agency (DLA).
- **FebriDx CLIA Waiver Study** continues with around 351 patients tested to-date, including 37 bacterial-positive patients. Study completion and FDA application anticipated in 2H CY2025.
- **Hologic fFN project scope of work expansion signed** and expected to generate an additional US$0.6-US$0.8 million in fee revenue.
- **ISO 13485:2016 and the Medical Device Single Audit Program (MDSAP)** audit surveillance successfully passed.
- **Cash balance of US$4.0 million** as at 31 March 2025.
- **Operating cashflow significantly improved,** with an operating cash outflow of US$1.3 million, compared with US$3.7 million in Q2 FY25.
- **Post Reporting Date: Medicare payor coverage adoption commences –** FebriDx® added to Medicare Fee Schedule in Palmetto, Novitas, First Coast Service Options and Noridian regions at $41.38 per test, effective April 2025, with discussions in the three remaining Medicare Administration Contractors progressing.

***All amounts are in USD, the Company's reporting currency, unless otherwise stated.***

**MELBOURNE, Australia (29 April 2025)** – Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") a leader in rapid point-of-care diagnostic technologies, is pleased to release its Quarterly Activity Statement and Appendix 4C Quarterly Cash Flow Report for the third quarter of FY25 (Q3 FY25 / the three months ended 31 March 2025).

**Operational Update**

Lumos recorded unaudited revenue of US$3.5 million for the quarter ended 31 March 2025, down 13%, compared with Q3 FY24, but up 21% compared to Q2 FY25.

Revenue generated during the quarter from the Services business was US$2.8 million, with the Hologic fFN Development Agreement and the Intellectual Property licensing revenue associated with the Hologic IP Agreement generating the majority of revenue. The 16% decline on PCP was primarily due to the reduced monthly revenue recognition rate of the Intellectual Property Agreement (US$10.0 million upfront payment) from US$0.50 million to US$0.37 million per month, and a reduction in the revenue recognized from the Development Agreement from US$0.24 million per month to US$0.17 million. This was due to the extended project timeline, announced at the time of the Q2 FY25 results.

Revenue from the Products business during the quarter was US$0.7 million, up 17% on the Q2 revenue. Following additional sales in the UK and growing adoption in the US, FebriDx® sales continue to grow, with revenue increasing 48% on PCP. Binx sales grew strongly during the period, up 73% on PCP, benefiting from repeat sales to existing customers and increasing customer awareness. ViraDx™ continued to generate the majority of revenue from Products. However, as previously outlined, competitive pressures from Chinese and South Korean suppliers resulted in an 11% decline in sales on PCP.

During the quarter, Lumos successfully completed its “Surveillance 2” audits to maintain ISO 13485:2016 and Medical Device Single Audit Program (MDSAP) certifications. Each audit resulted in zero findings, demonstrating the robustness and maturity of Lumos' quality management system (QMS). ISO 13485:2016 is the international standard for a Quality Management System that is specific to medical devices covering areas such as design, development, and good manufacturing practices (GMP). MDSAP adds an extra layer to the audit and is used in conjunction with ISO 13485 to demonstrate compliance with both the standard and the regulatory requirements of multiple jurisdictions, including the US, Canada, and Australia where Lumos’ products are sold.

**Development Services and Contract Manufacturing Division**

Lumos generated US$2.8 million from the provision of diagnostic test and custom reader development services, contract manufacturing and IP license revenue during the March quarter. Development services included ongoing project work for Hologic, Burnet Diagnostics Initiative, Huvepharma and other customers.

*Hologic*

On 11 January 2024, Lumos announced an IP and Development agreement with Hologic, a leading global women’s health provider, to develop the next generation of Hologic’s on-market fFN diagnostic product for pre-term birth, for which Hologic is the only global manufacturer. A key focus of the development program is to adapt the test for use on the Lumos proprietary reader platform and provide improved connectivity options.

On 3 March 2025, an agreement was signed to extend the project’s scope of work. This expanded agreement relates to Phase 3 of the Development Agreement, which focuses on the delivery of the system

prototype. Phase 3 will now include incorporating additional hardware features into the proprietary reader technology. The expanded scope of work is estimated to generate additional fee-revenue for Lumos of between US$0.6 - US$0.8 million, to be invoiced as the work is completed over the coming months.

As previously announced, the body of work under the Development Agreement is being conducted across three phases, providing total milestone payments of up to US$4.7 million, structured as follows:

- Phase 1 - Product Definition and Planning: define the parameters for the product and establish a project plan - US$0.4 million - completed as announced on 6 May 2024. Payment has been received for this phase;
- Phase 2 - Assay Feasibility: conduct work to demonstrate the assay can detect the biomarkers - US$0.6 million – work on the first milestone of this phase has been completed, comprising US$0.3 million payment, as announced on 20 September 2024, and payment has been received. Work on the second and final milestone for this phase, worth $0.3 million is ongoing and expected to complete by around May 2025; and
- Phase 3 - System Prototype Delivery: deliver a working prototype of the system - US$3.7 million – the first of six Phase 3 milestones is in progress, with work on this phase expected to complete by around December 2025.

The value of this Phase 3, including the expanded scope of works is now expected to be between US$4.3 – US$4.5 million, bringing the total value of the Development Agreement to around US$5.3 - US$5.5 million.

As announced in Lumos' Q2 FY25 quarterly report (ASX: 31 January 2025), the total project timeline is now expected to take around 24 months to complete, running from January 2024 to December 2025, including the additional hardware scope of works.

*Burnet Diagnostics Initiative (BDI)*

On 26 August 2024, Lumos announced an extension of its existing agreement with Burnet Diagnostics Initiative (BDI) to manufacture a lateral flow test developed at the BDI and develop and manufacture customised Lumos readers to monitor liver function in an upcoming US based clinical trial. As part of this engagement, Lumos will perform development, regulatory and manufacturing services over a 9 - 12 month period, generating fees of between US$0.7 million and US$1.0 million.

By the end of March 2025, Lumos had successfully completed production of Alanine Transaminase (ALT) lateral flow test kits and customized Lumos camera readers for BDI. BDI's US based clinical trial began in February 2025 and is likely to be expanded into Australian clinical trials later in calendar 2025.

**Products Division**

Despite softer sales revenue from ViraDx™, both FebriDx® and Binx reported stronger sales during the quarter on the PCP, as outlined above. We provide a summary of the following product updates below.

*FebriDx®*

FebriDx® is Lumos' rapid, point-of-care test which can be used to detect and aid in the diagnosis of acute bacterial disease states from respiratory infections. To date, Lumos has received regulatory registrations for the use of FebriDx® in the United States, UK, Europe, Canada, UAE and Australia. During the quarter, FebriDx® achieved a number of pivotal milestones.

**CLIA Waiver Study Update:** Lumos commenced the pivotal FebriDx® CLIA waiver study in the United States, with the first patient successfully tested on 19 December 2024. It is anticipated that between 500 – 800 patients will need to be enrolled across at least six sites to achieve the required 120 positive bacterial cases for the study.

To date, bacterial prevalence amongst patients has been lower than expected, with around 37 bacterial positive results (10.5%) of the 351 patients tested by the end of Q3 FY25. To assist in accelerating the study, a patient enrollment "enrichment" plan has been implemented in late March. Completion of the study is now anticipated to be around September 2025, with an application for CLIA waiver labelling for FebriDx expected to be lodged with the U.S. FDA by calendar year end.

Under the BARDA partnership, the next milestone payment of US$0.3 million will be triggered upon the testing of the 500$^{th}$ patient, which is expected to occur around June 2025.

**Distribution Agreements:** In January 2025, Lumos announced a partnership with MedPro Associates for national contract sales coverage for FebriDx® across hospital and primary care markets in the U.S. MedPro's national team of more than 60 territory representatives will provide sales representation, training, and in-servicing for the FebriDx® test in the U.S. Lumos completed the launch and training activities for the entire MedPro organization during January and field activity is already positive.

Also in January, the U.S. Defense Logistics Agency (DLA) awarded FebriDx® a Distribution and Pricing Agreement (DAPA) under the DLA Troop Support Medical Supply Chain Acquisition Program. This agreement authorizes FebriDx® sales representatives to promote the product to the U.S. Military Services; however, it does not guarantee procurement.

Looking ahead, Lumos anticipates FebriDx® will be added to the DLA's Electronic Catalog (ECAT) around June 2025, with inclusion in the Federal Supply Schedule (FSS) expected by August 2025. The FSS listing will provide Veterans Administration (VA) hospitals with the ability to purchase FebriDx® directly, though they will also have the option to procure it through the DAPA in the interim.

**Medicare Benefits Schedule Application - Australia:** In late March, Lumos completed and lodged an application with the Australian Government Department of Health and Aged Care for the inclusion of FebriDx® on the Medicare Benefits Schedule.

**Post Reporting Date: Medicare US Payor coverage adoption commences:** On 5 December 2024, Lumos received approval from the Centers for Medicare and Medicaid Services (CMS) Panel for the FebriDx® Proprietary Laboratory Analyses (PLA) code 0442U, to be reimbursed at a rate of US$41.38 per test. The FebriDx® PLA code was published on the Clinical Lab Fee Schedule and took effect on 1 January 2025.

Securing the reimbursement rate from CMS via PLA Code 0442U was a critical first step. Payment (coverage) of the PLA Code to healthcare providers by the payors (Medicare and private insurance) is not automatic and must be secured. Lumos has executed a strategy of seeking comprehensive Medicare coverage for FebriDx®. Medicare comprises approximately 20% –24% of the U.S. payor mix and often sets a precedent for private payors. Lumos has now engaged with all seven Medicare Administrative Contractors (MACs) and is seeing positive early momentum:

- Effective from April 2025, FebriDx® has been added to the Medicare Fee Schedule in four of the seven MAC regions - the Palmetto, Novitas, First Coast Service Options and Noridian regions, at US$41.38 per test.
- With these regions, Lumos now has Medicare reimbursement representing over 55% of the total US Medicare payment coverage.
- Discussions are well progressed with the remaining three regions - WPS, NGS and CGS = with next steps underway to formalize inclusion to their Medicare Fee Schedule.

Importantly, the reimbursement pathway already encompasses both Moderately Complex and CLIA-Waived settings. Should Lumos be successful with having FebriDx® CLIA waived, this will in time allow FebriDx® to seamlessly transition across the two testing environments, without repeating the reimbursement process.

**Supply Agreement with Atomo Diagnostics for FebriDx Raw Materials:** During April, Lumos completed an updated and amended Supply Agreement with Atomo Diagnostics (ASX: AT1) for the supply of and licensing of intellectual property for Atomo's Pascal cassette, which is used in the FebriDx® test. The amended agreement extends the contract until 30 June 2031, maintains exclusivity to Lumos for the applicable FebriDx® test field with CLIA waiver, and contains other customary clauses for supply agreements.

*ViraDx™*

ViraDx™ is a rapid point-of-care diagnostic product that simultaneously tests for acute respiratory infections caused by the COVID-19, influenza A, and influenza B viruses.

ViraDx™ experienced the majority of its product sales during the second and third quarters, driven by stocking orders received in October, ahead of the anticipated US flu season. While the season commenced 6–8 weeks later than expected, demand accelerated into January in response to rising infection rates. This timing-shift aligned with broader trends observed across the US market.

Despite facing significant competition from international providers—particularly from China and South Korea, who have adopted aggressive pricing strategies—ViraDx™ successfully secured new customer adoption during the period as a result of the rising infection rates.

*Women's Sexual Health Product Development*

Good progress has been achieved in identifying and developing a pipeline of future women's sexual health point-of-care diagnostic tests. The company is currently exploring five potential products aimed at addressing key unmet needs in this important and growing healthcare segment. These initiatives form part of our broader commitment to improving access, convenience, and early detection through innovative diagnostic solutions designed specifically for women.

Of the five potential products, three are currently in the concept development stage, with two advancing to technical feasibility. These early milestones are encouraging and reflect the Company's disciplined and evidence-based approach to innovation. Lumos is targeting the transition of at least one of these products into formal product development within the next 6 - 8 months, as the Company continues to build a robust pipeline focused on delivering impactful solutions in women's health.

**Summary of Cash Receipts and Outflows**

The net operating cash outflow for Q3 FY25 was US$1.3 million, and an improvement of US$2.4 million versus the Q2 FY25 operating cash outflow of US$3.7 million.

Lumos generated cash receipts from customers of US$1.5 million for the third quarter, ended 31 March 2025.

Cash operating expenses for Q3 were US$3.7 million, a decrease of US$1.8 million or 33% over Q2 FY25 expenses of $5.5 million. This was primarily due to lower costs associated with inventory build-up leading into the U.S. flu season and pre-clinical trial costs associated with the CLIA Waiver study and other general operating costs.

Lumos received US$0.9 million from BARDA during the quarter, representing a refund of costs incurred by Lumos in Q1 and Q2 FY25, relating to the planning, pilots and establishment of the FebriDx CLIA Waiver study.

As in prior quarters, there was essentially no capital expenditure during Q3 FY25.

After including investing activities, and lease payment expenses, net cash outflow for the quarter totaled US$1.6 million.

Lumos finished Q3 FY25 with a cash balance of US$4.0 million.

**Payments to Related Entities**

In accordance with Listing Rule 4.7C.3 and as outlined in Section 6.1 of Appendix 4C, the Company discloses payments to related entities of US$221,000 comprising directors' fees, consulting fees, salary & wages and superannuation.

**Key Priorities**

The key focus areas for Lumos are currently summarized as follows:

- Implement bacterial positive enrichment strategy for the FebriDx® CLIA waiver trial to accelerate the study
- FDA pre-submission for the FebriDx® pediatric study
- Continue to drive FebriDx® product awareness and sales into U.S. urgent care centers
- Continue to expand payor coverage in the U.S., both government and private, for FebriDx
- Deliver on Hologic fFN development milestones – including milestone 2 from Phase 2 & Phase 3 milestones, including the additional hardware scope of works
- Progress to formal product development on the first Lumos branded women's health diagnostics test

**In closing, CEO, Doug Ward noted:** *"It was pleasing to see that we continued to make strategic progress during and following quarter's end. The growth in our FebriDx® sales - particularly in the US and UK - demonstrates the underlying strength and market appetite for our proprietary technology. Importantly, we've made significant headway in our U.S. market access strategy, with FebriDx® now added to the Medicare Fee Schedule in several key regions and discussions progressing across the remaining three Medicare Administrative Contractors. In time, we would expect US private payors to follow the leads of the public payors."*

*"The FebriDx® CLIA waiver study is progressing, and with the recent implementation of our enrichment strategy, we're confident in reaching the study's completion and FDA application later this year."*

*"Our partnership and development work with Hologic continues to advance, with an expanded scope of work that not only strengthens the collaboration but also drives incremental fee revenue. This is a strong endorsement of our reader technology platform and development capabilities, and we're proud to be assisting in the development of the next generation of critical diagnostic solutions."*

*"As we look ahead, our focus remains on accelerating commercial traction in the U.S., delivering on key development milestones, and expanding access to our innovative diagnostics. With Medicare coverage now underway for FebriDx, growing distribution partnerships, and a robust development pipeline for women's sexual health point-of-care diagnostics, we are well-positioned to drive sustained revenue growth and create long-term value for our shareholders."*

**Investor Briefing**

The Company invites investors and analysts to attend an online briefing on Tuesday, 6 May 2025 at 10.15am (AEST).

During the briefing, Chief Executive Officer, Doug Ward and Chief Financial Officer, Barrie Lambert will present an overview of the results and discuss recent progress. This will be followed by a Q+A session.

Participants can pre-register ahead of time via the following link:

https://us02web.zoom.us/webinar/register/WN_Xd-kNBDSQOaD-mrb8pvh4A

Once the registration form is completed, investors will receive a confirmation email with details on how to access the briefing. If you would like to ask a question during the briefing, please send your question ahead of the session to: george.kopsiaftis@irdepartment.com.au.

The Lumos team looks forward to welcoming those shareholders and potential investors who are able to attend.

**-Ends-**

***This announcement has been approved by the Lumos Disclosure Committee.***

**About Lumos Diagnostics**

*Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.*

*For more information visit lumosdiagnostics.com.*

**Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

**Media Contacts:**
Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

**Investor Contact:**
George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

**Company Registered Office:**
Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
info@lumosdiagnostics.com
+61 3 9087 1598

# Appendix 4C

## Quarterly Cash Flow report for entities subject to Listing Rule 4.7B



**Name of entity**

Lumos Diagnostics Holding Limited

| **ABN** | **Quarter ended ("current quarter")** |
|---|---|
| 66 630 476 970 | 31 March 2025 |

| **Consolidated statement of cash flows** | | **Current quarter US$'000** | **Year to date (9 months) US$'000** |
|---|---|---|---|
| **1.** | **Cash flows from operating activities** | | |
| 1.1 | Receipts from customers | 1,539 | 4,548 |
| 1.2 | Payments for | | |
| | (a) service delivery, research and development | (882) | (2,605) |
| | (b) product manufacturing and operating costs | (651) | (2,676) |
| | (c) sales, advertising and marketing | (328) | (1,070) |
| | (d) medical affairs and clinical trial costs | (231) | (745) |
| | (e) leased assets | - | - |
| | (f) staff costs* | (1,017) | (4,001) |
| | (g) administration and corporate costs | (546) | (1,715) |
| 1.3 | Dividends received (see note 3) | - | - |
| 1.4 | Interest received | 11 | 50 |
| 1.5 | Interest and other costs of finance paid | (144) | (444) |
| 1.6 | Income taxes paid | - | - |
| 1.7 | Government grants and tax incentives | 925 | 1,018 |
| 1.8 | Other (provide details if material) | - | - |
| **1.9** | **Net cash from / (used in) operating activities** | **(1,324)** | **(7,640)** |

*Staff costs have been allocated to their respective departments above.

| | | | |
|---|---|---|---|
| **2.** | **Cash flows from investing activities** | | |
| 2.1 | Payments to acquire or for: | | |
| | (a) entities | - | - |
| | (b) businesses | - | - |
| | (c) property, plant and equipment | (8) | (25) |
| | (d) investments | - | - |

| Consolidated statement of cash flows | | Current quarter US$'000 | Year to date (9 months) US$'000 |
|---|---|---|---|
| | (e) intellectual property | - | - |
| | (f) other non-current assets (including capitalised product development costs) | - | - |
| 2.2 | Proceeds from disposal of: | | |
| | (a) entities | - | - |
| | (b) businesses | - | - |
| | (c) property, plant and equipment | - | - |
| | (d) investments | - | - |
| | (e) intellectual property | - | - |
| | (f) other non-current assets | - | - |
| 2.3 | Cash flows from loans to other entities | - | - |
| 2.4 | Dividends received (see note 3) | - | - |
| 2.5 | Other (provide details if material) | - | - |
| **2.6** | **Net cash from / (used in) investing activities** | **(8)** | **(25)** |

| | | | |
|---|---|---|---|
| **3.** | **Cash flows from financing activities** | | |
| 3.1 | Proceeds from issues of equity securities (excluding convertible debt securities) | - | 6,765 |
| 3.2 | Proceeds from issue of convertible debt securities | - | - |
| 3.3 | Proceeds from exercise of options | - | - |
| 3.4 | Transaction costs related to issues of equity securities or convertible debt securities | - | (543) |
| 3.5 | Proceeds from borrowings | - | - |
| 3.6 | Repayment of borrowings | - | - |
| 3.7 | Transaction costs related to loans and borrowings | - | - |
| 3.8 | Dividends paid | - | - |
| 3.9 | Other: | | |
| | Lease payments (principal component) | (251) | (689) |
| **3.10** | **Net cash from / (used in) financing activities** | **(251)** | **5,533** |

| Consolidated statement of cash flows | | Current quarter US$'000 | Year to date (9 months) US$'000 |
|---|---|---|---|
| **4.** | **Net increase / (decrease) in cash and cash equivalents for the period** | | |
| 4.1 | Cash and cash equivalents at beginning of period | 5,532 | 6,479 |
| 4.2 | Net cash from / (used in) operating activities (item 1.9 above) | (1,324) | (7,640) |
| 4.3 | Net cash from / (used in) investing activities (item 2.6 above) | (8) | (25) |
| 4.4 | Net cash from / (used in) financing activities (item 3.10 above) | (251) | 5,533 |
| 4.5 | Effect of movement in exchange rates on cash held | 25 | (373) |
| **4.6** | **Cash and cash equivalents at end of period** | **3,974** | **3,974** |

| **5.** | **Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | Current quarter US$'000 | Previous quarter US$'000 |
|---|---|---|---|
| 5.1 | Bank balances | 3,974 | 5,532 |
| 5.2 | Call deposits | - | - |
| 5.3 | Bank overdrafts | - | - |
| 5.4 | Other (provide details) | - | - |
| **5.5** | **Cash and cash equivalents at end of quarter (should equal item 4.6 above)** | **3,974** | **5,532** |

| **6.** | **Payments to related parties of the entity and their associates** | Current quarter US$'000 |
|---|---|---|
| 6.1 | Aggregate amount of payments to related parties and their associates included in item 1 | 221 |
| 6.2 | Aggregate amount of payments to related parties and their associates included in item 2 | - |

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

| 7. | **Financing facilities**<br>*Note: the term "facility' includes all forms of financing arrangements available to the entity.*<br>*Add notes as necessary for an understanding of the sources of finance available to the entity.* | **Total facility amount at quarter end US$'000** | **Amount drawn at quarter end US$'000** |
|---|---|---|---|
| 7.1 | Loan facilities | - | - |
| 7.2 | Credit standby arrangements | - | - |
| 7.3 | Other (please specify) | 2,500 | - |
| 7.4 | **Total financing facilities** | 2,500 | - |

| | | |
|---|---|---|
| 7.5 | **Unused financing facilities available at quarter end** | 2,500 |

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

The company put in place an A$8.0m convertible note facility which was approved by shareholders at the general meeting on 22 December 2022. The facility is comprised of Tranche 1 of $A4.0m and Tranche 2 of A$4.0m (before costs).

The company completed the draw down and settlement of Tranche 1 on 5 January 2023, with the balance owed subsequently repaid in full on 10 August 2023.

The use of Tranche 2 for A$4.0m (before costs) is subject to mutual agreement between the company and the two convertible note investors.

Amounts shown above are for Tranche 2 based on an FX rate of A$1.00:US$0.6251.

| 8. | **Estimated cash available for future operating activities** | **US$'000** |
|---|---|---|
| 8.1 | Net cash from / (used in) operating activities (item 1.9) | (1,324) |
| 8.2 | Cash and cash equivalents at quarter end (item 4.6) | 3,974 |
| 8.3 | Unused finance facilities available at quarter end (item 7.5) | 2,500 |
| 8.4 | Total available funding (item 8.2 + item 8.3) | 6,474 |
| 8.5 | **Estimated quarters of funding available (item 8.4 divided by item 8.1)** | 4.9x |

*Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.*

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

| | |
|---|---|
| 8.6.3 | Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis? |
| Answer: N/A | |
| *Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.* | |

## Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: **29 April 2025**

Authorised by: **The Lumos Disclosure Committee**
(Name of body or officer authorising release – see note 4)

**Notes**

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.